Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725868 | 0.88 | CTSL (0.60) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4342809 | 0.86 | CTRB1 (0.53) | CTRB1ATMCTSKELANECTSS | |
| SCHEMBL13823084 | 0.84 | CTSK (0.57) | CTRB1ATMCTSKELANECTSS | |
| SCHEMBL16460328 | 0.81 | CTSK (0.63) | CTRB1CTSKCTSSCTSLCTSB | |
| SCHEMBL16460327 | 0.81 | CTSK (0.63) | CTRB1CTSKCTSSCTSLCTSB | |
| SCHEMBL2952202 | 0.80 | CTSK (0.56) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL29521267 | 0.80 | CTSK (0.56) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL2952201 | 0.80 | CTSK (0.56) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL7372298 | 0.79 | ATM (0.61) | CTRB1ATMCTSKELANECTSS | |
| SCHEMBL308291 | 0.79 | ATM (0.64) | CTRB1ATMCTSKELANECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2009-07-02 | — | — | US | disclosed |
| CN-100382795-C | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2008-04-23 | — | — | CN | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060188920-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | BALZARINI JAN MARIA R | 2006-08-24 | — | — | US | disclosed |
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | BALZARINI JAN MARIA R | 2006-08-17 | — | — | US | disclosed |
| CN-1777414-A | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| EP-1603546-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | Tripep AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | TRIPEP AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | GALE, ENGASE, GLMN | CTRB1 2060/4885ATM 4561/4885CTSK 1343/4885 |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | GALE, ENGASE, GLMN | CTRB1 2676/4885ATM 4416/4885CTSK 1908/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CTRB1 3205/4885ATM 4714/4885CTSK 2645/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | CTRB1 1441/4885ATM 4023/4885CTSK 1358/4885 |
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | OGA, ENGASE, GALE | CTRB1 3502/4885ATM 4052/4885CTSK 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.